Abstract
The angiotensin receptor blocker (ARB) telmisartan is a partial agonist of peroxisome proliferator–activated receptor γ (PPARγ). Typical PPARγ agonists suppress the gene expression of angiotensin-converting enzyme (ACE) in vascular tissues. However, it remains unclear whether or not PPARγ activation by telmisartan can inhibit vascular ACE activity. We compared the effects of PPARγ agonistic telmisartan and non-agonistic valsartan on ACE, vascular function and oxidative stress in stroke-prone spontaneously hypertensive rats (SHR-SP) and in sodium (1% NaCl)-loaded SHR-SP. SHR-SP and sodium-loaded SHR-SP received placebo, 1 mg/kg telmisartan, or 10 mg/kg valsartan for 2 weeks. Systolic blood pressure (SBP) was equally reduced in SHR-SP given either telmisartan or valsartan compared with SHR-SP given placebo. However, neither telmisartan nor valsartan suppressed SBP in sodium-loaded SHR-SP. Acetylcholine induced significantly less vasorelaxation in SHR-SP than in Wistar-Kyoto rats, but telmisartan and valsartan each significantly prevented such vasorelaxation. However, telmisartan significantly attenuated acetylcholine-induced vasorelaxation in sodium-loaded SHR-SP, whereas valsartan did not. Telmisartan significantly attenuated NADPH oxidase subunit p22phox gene expression in both SHR-SP and sodium-loaded SHR-SP, whereas valsartan did not. Likewise, telmisartan also significantly attenuated the significantly increased vascular ACE activity in sodium-loaded SHR-SP, whereas valsartan did not. In conclusion, the partial PPARγ agonist telmisartan might inhibit vascular ACE activity, and result in the prevention of oxidative stress and endothelial dysfunction more effectively than non-agonistic valsartan.
Similar content being viewed by others
Article PDF
References
Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43: 993–1002.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U : Angiotensin type 1 receptor blockers induce peroxisome proliferator–activated receptor-γ activity. Circulation 2004; 109: 2054–2057.
Picard F, Auwerx J : PPARγ and glucose homeostasis. Annu Rev Nutr 2002; 22: 167–197.
Toba H, Miki S, Shimizu T, et al: The direct antioxidative and anti-inflammatory effects of peroxisome proliferator–activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta. Eur J Pharmacol 2006; 549: 124–132.
Kanemitsu H, Takai S, Tsuneyoshi H, et al: Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res 2006; 29: 57–64.
Kirimura K, Takai S, Jin D, et al: Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens Res 2005; 28: 457–464.
Takai S, Kirimura K, Jin D, et al: Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593–600.
Tanaka H, Takai S, Jin D, et al: Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res 2007; 30: 469–475.
Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W : Differential expression of peroxisome proliferator–activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 1996; 137: 354–366.
Fernandez-Alfonso MS, Kreutz R, Zeh K, Liu Y, Ganten D, Paul M : Differential regulation of vascular angiotensin I–converting enzyme in hypertension. Hypertension 1994; 24: 280–286.
Takai S, Jin D, Sakaguchi M, Miyazaki M : Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res 2004; 27: 213–219.
Verma S, Bhanot S, McNeill JH : Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 1998; 56: 7–16.
Grinsell JW, Lardinois CK, Swislocki A, et al: Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens 2000; 13: 370–375.
Wakino S, Hayashi K, Tatematsu S, et al: Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255–262.
Campia U, Matuskey LA, Panza JA : Peroxisome proliferator–activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867–875.
Fukui T, Ishizaka N, Rajagopalan S, et al: p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45–51.
Ulker S, McMaster D, McKeown PP, Bayraktutan U : Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res 2003; 59: 488–500.
Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF : NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 2002; 40: 755–762.
Inoue I, Goto S, Matsunaga T, et al: The ligands/activators for peroxisome proliferator–activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001; 50: 3–11.
Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK : Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406–413.
Takai S, Sakonjo H, Miyazaki M : Beneficial effect of trandolapril on the lifespan of a severe hypertensive model. Hypertens Res 2001; 24: 559–564.
Morishita R, Higaki J, Nakamura F, et al: Regression of hypertension-induced vascular hypertrophy by an ACE inhibitor and calcium antagonist in the spontaneously hypertensive rat. Blood Press 1992; 3 ( Suppl): 41–47.
Mizuno K, Niimura S, Katoh K, Fukuchi S : TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. Life Sci 1994; 54: 1987–1994.
Diep QN, Amiri F, Benkirane K, Paradis P, Schiffrin EL : Long-term effects of the PPAR γ activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Can J Physiol Pharmacol 2004; 82: 976–985.
Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW : Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003–1009.
Mori Y, Itoh Y, Tajima N : Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2007; 20: 431–436.
Ishibashi M, Egashira K, Hiasa K, et al: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687–693.
Imayama I, Ichiki T, Inanaga K, et al: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator–activated receptor γ. Cardiovasc Res 2006; 72: 184–190.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takai, S., Jin, D., Kimura, M. et al. Inhibition of Vascular Angiotensin-Converting Enzyme by Telmisartan via the Peroxisome Proliferator–Activated Receptor γ Agonistic Property in Rats. Hypertens Res 30, 1231–1237 (2007). https://doi.org/10.1291/hypres.30.1231
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.1231
Keywords
This article is cited by
-
Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension
Current Hypertension Reports (2018)
-
Effects of renin–angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet
Acta Diabetologica (2013)
-
Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease
Journal of Neuroinflammation (2012)
-
Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats
Hypertension Research (2011)
-
Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats
Hypertension Research (2009)